Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex
Analysis of resistance mechanisms to abivertinib, a third-generation EGFR tyrosine kinase inhibitor, in patients with EGFR T790M-positive non-small cell lung cancer from a phase I trial
PaperCitations, authors & open-access status
Analysis of resistance mechanisms to abivertinib, a third-generation EGFR tyrosine kinase inhibitor, in patients with EGFR T790M-positive non-small cell lung cancer from a phase I trial is a paper indexed in ScholarIQ from OpenAlex. ScholarIQ records 46 citations, 2019 year and gold oa status.
46
Citations
2019
Year
gold
OA Status